These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38972199)

  • 1. High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS.
    Rosén C; Mitre B; Nellgård B; Axelsson M; Constantinescu R; Andersen PM; Dalla K; Blennow K; Nilsson G; Zetterberg H; Rosén H
    J Neurol Sci; 2024 Aug; 463():123112. PubMed ID: 38972199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
    Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
    J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.
    Illán-Gala I; Alcolea D; Montal V; Dols-Icardo O; Muñoz L; de Luna N; Turón-Sans J; Cortés-Vicente E; Sánchez-Saudinós MB; Subirana A; Sala I; Blesa R; Clarimón J; Fortea J; Rojas-García R; Lleó A
    Neurology; 2018 Oct; 91(17):e1619-e1628. PubMed ID: 30291183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase.
    Oeckl P; Weydt P; Steinacker P; Anderl-Straub S; Nordin F; Volk AE; Diehl-Schmid J; Andersen PM; Kornhuber J; Danek A; Fassbender K; Fliessbach K; ; Jahn H; Lauer M; Müller K; Knehr A; Prudlo J; Schneider A; Thal DR; Yilmazer-Hanke D; Weishaupt JH; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):4-10. PubMed ID: 30224549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Shahim P; Norato G; Sinaii N; Zetterberg H; Blennow K; Chan L; Grunseich C
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis.
    Steinacker P; Fang L; Kuhle J; Petzold A; Tumani H; Ludolph AC; Otto M; Brettschneider J
    PLoS One; 2011; 6(8):e23600. PubMed ID: 21858182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
    Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
    Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
    Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij HB; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF chitinase proteins in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of CSF NfL and tau in ALS.
    Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
    J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies.
    Vrillon A; Bousiges O; Götze K; Demuynck C; Muller C; Ravier A; Schorr B; Philippi N; Hourregue C; Cognat E; Dumurgier J; Lilamand M; Cretin B; Blanc F; Paquet C
    Alzheimers Res Ther; 2024 Jul; 16(1):146. PubMed ID: 38961441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
    Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
    JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia.
    Abu-Rumeileh S; Steinacker P; Polischi B; Mammana A; Bartoletti-Stella A; Oeckl P; Baiardi S; Zenesini C; Huss A; Cortelli P; Capellari S; Otto M; Parchi P
    Alzheimers Res Ther; 2019 Dec; 12(1):2. PubMed ID: 31892365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
    Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
    Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid and blood neurofilament light chain levels in amyotrophic lateral sclerosis and frontotemporal degeneration: A meta-analysis.
    Verde F; Licaj S; Soranna D; Ticozzi N; Silani V; Zambon A
    Eur J Neurol; 2024 Sep; 31(9):e16371. PubMed ID: 38937912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression.
    Andrés-Benito P; Domínguez R; Colomina MJ; Llorens F; Povedano M; Ferrer I
    Aging (Albany NY); 2018 Sep; 10(9):2367-2382. PubMed ID: 30215603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.